Epithalon — Wolverine Health

How it works

A synthetic tetrapeptide based on epithalamin, a pineal gland extract researched by the St. Petersburg Institute of Bioregulation since the 1980s. The anti-aging angle: it reportedly activates telomerase and extends telomere length in cell culture. Rodent lifespan studies from that same research group show extended mean lifespan. The telomerase story is interesting. It's also mostly from one lab, in animals, using in vitro measures. Human evidence doesn't yet exist in a rigorous form.

FDA status: No FDA approval. Under PCAC July 23–24 2026 review for 503A bulk substance consideration.
WADA status: Permitted in sport
Route: subcutaneous or intramuscular injection; intranasal

Key studies

Epithalone activates telomerase and elongates telomeres — Khavinson et al. (2003)

Epithalon (Ala-Glu-Asp-Gly) activated telomerase in fetal human fibroblasts and somatic cells, with increased telomere elongation observed in treated cell cultures compared with controls.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on Epithalon

What RFK Jr.'s February 2026 announcement actually said about peptides

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

After the PCAC votes: what FDA reclassification actually looks like in practice

A favourable July PCAC vote is not a prescription you can fill in August. The rulemaking that follows the recommendation is where your access actually changes — and where the legitimate supply chain starts to exist.

The PCAC review is July 23–24, 2026. Here is what that means for peptide access.

Two days at FDA's White Oak campus decide which of seven peptides US compounding pharmacies will be allowed to dispense by prescription. The vote is not an approval, the docket is not all the peptides, and the framing the forums use is mostly wrong.

Telomeres, explained: the countdown inside your cells — and why longevity science keeps circling it

WADA

Telomeres cap your chromosomes, and get shorter every time a cell divides. Reset that countdown and you'd slow ageing itself — the longevity holy grail. Here's the real biology, what could move it, and why telomere-lengthening as anti-ageing is still unproven in humans.

MOTs-C vs Epitalon: two different bets on ageing slower

WADA

MOTs-C and Epitalon are two very different longevity bets — one on your metabolism, one on the clock inside your cells. Here is what each could do for you, which angle fits your goal, and how far the human proof goes on both.

Epithalon and the cellular clock: the telomere longevity case, in full

WADA

The whole longevity case for Epithalon rests on one idea — switching telomerase back on to rebuild the caps on your chromosomes. Here is how deep the telomere evidence really goes, what the Russian program does and doesn't prove, and where the honest line sits.

Epithalon: the four-amino-acid peptide betting it can slow your clock

WADA

Epithalon is the shortest peptide on the longevity menu, built on one bold idea — switching telomerase back on to rebuild the caps on your chromosomes. Here is what it could do for you, how far the proof actually goes, and where it sits on the July 2026 PCAC docket.